You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
|
|---|---|
| Published in |
The Lancet, November 2012
|
| DOI | 10.1016/s0140-6736(12)61769-3 |
| Pubmed ID | |
| Authors |
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher, Vesna V Brinar, Gavin Giovannoni, Miroslav Stojanovic, Bella I Ertik, Stephen L Lake, David H Margolin, Michael A Panzara, D Alastair S Compston, for the CARE-MS I investigators |
| Abstract |
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 17% |
| United States | 3 | 13% |
| Switzerland | 1 | 4% |
| United Kingdom | 1 | 4% |
| Gibraltar | 1 | 4% |
| Argentina | 1 | 4% |
| Unknown | 13 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 83% |
| Practitioners (doctors, other healthcare professionals) | 2 | 8% |
| Scientists | 1 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 773 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | <1% |
| United States | 3 | <1% |
| Germany | 2 | <1% |
| Portugal | 2 | <1% |
| Brazil | 2 | <1% |
| Netherlands | 2 | <1% |
| Argentina | 2 | <1% |
| United Kingdom | 2 | <1% |
| Austria | 1 | <1% |
| Other | 9 | 1% |
| Unknown | 745 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 117 | 15% |
| Other | 91 | 12% |
| Student > Bachelor | 91 | 12% |
| Student > Ph. D. Student | 77 | 10% |
| Student > Master | 69 | 9% |
| Other | 175 | 23% |
| Unknown | 153 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 304 | 39% |
| Neuroscience | 72 | 9% |
| Agricultural and Biological Sciences | 54 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 30 | 4% |
| Biochemistry, Genetics and Molecular Biology | 27 | 3% |
| Other | 91 | 12% |
| Unknown | 195 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 137. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2024.
All research outputs
#308,334
of 26,017,215 outputs
Outputs from The Lancet
#3,253
of 43,155 outputs
Outputs of similar age
#1,582
of 206,812 outputs
Outputs of similar age from The Lancet
#20
of 431 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 43,155 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,812 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 431 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.